Cargando…

Immunohistochemical Analysis of BRAF (V600E) Mutation and P16 Expression in Malignant Melanoma in Lagos, Nigeria: A 10-Year Retrospective Study

BACKGROUND: In Blacks, malignant melanoma (MM) is associated with greater morbidity and mortality compared to Caucasians. MMs with BRAF V600E mutation as well as those with loss of p16 protein expression are associated with aggressive behavior and worse prognosis. OBJECTIVES: We determined BRAF (V60...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obadofin, O., Badmos, K., Orsi, N., Bipin, M., Rotimi, O., Banjo, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500614/ https://www.ncbi.nlm.nih.gov/pubmed/31139472 http://dx.doi.org/10.1155/2019/1628247

Ejemplares similares

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

Review of immunohistochemical typing of endometrial carcinoma at the Lagos University Teaching Hospital
por: Dawodu, Olayemi Olubunmi, et al.
Publicado: (2019)

Breast Cancer Reporting in Lagos, Nigeria: Implications for Training and Education in Africa
por: Daramola, Adetola O., et al.
Publicado: (2016)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

BRAF(V600E )mutations in malignant melanoma are associated with increased expressions of BAALC
por: Schrama, David, et al.
Publicado: (2008)

BRAF V600E mutational load as a prognosis biomarker in malignant melanoma
por: Sevilla, Arrate, et al.
Publicado: (2020)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
por: Ponti, Giovanni, et al.
Publicado: (2012)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Kaposi Sarcoma among HIV Infected Patients in Lagos University Teaching Hospital, Nigeria: A 14-Year Retrospective Clinicopathological Study
por: Akinde, Olakanmi, et al.
Publicado: (2016)

Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma
por: Tang, Hsin-Chieh, et al.
Publicado: (2015)

Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer
por: Matsuzawa, Reiko, et al.
Publicado: (2021)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

Comparative BRAF V600E immunohistochemical expression in differentiated thyroid tumors with papillary features
por: Wahid, Maha Hatem Abdul, et al.
Publicado: (2022)

Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
por: Kocovski, Linda, et al.
Publicado: (2015)

BRAF V600 mutations and pathological features in Japanese melanoma patients
por: Yamazaki, Naoya, et al.
Publicado: (2015)

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot
por: Iwama, Eimei, et al.
Publicado: (2015)

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens
por: Løes, Inger Marie, et al.
Publicado: (2014)

Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria
por: Haruna, Muibat, et al.
Publicado: (2022)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
por: Zepeda-Lopez, Priscilla Denise, et al.
Publicado: (2016)

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
por: Banzi, Maria, et al.
Publicado: (2016)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene
por: Hall, Arnaldur, et al.
Publicado: (2013)

Self-medication for infants with colic in Lagos, Nigeria
por: Oshikoya, Kazeem A, et al.
Publicado: (2009)

Bacterial Vaginosis and Pregnancy Outcome in Lagos, Nigeria
por: Afolabi, Bosede B., et al.
Publicado: (2016)

Colonoscopy Practice in Lagos, Nigeria: A Report of an Audit
por: Onyekwere, C. A., et al.
Publicado: (2013)

Surgical outcomes of diabetic hand infections in Lagos, Nigeria
por: Mofikoya, Bolaji O, et al.
Publicado: (2019)

Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis
por: Ito, Takamichi, et al.
Publicado: (2019)

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF(V600) melanoma
por: Smith, Lorey K., et al.
Publicado: (2022)

Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder
por: Yu, Zhou, et al.
Publicado: (2018)

Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets
por: Improta, Giuseppina, et al.
Publicado: (2013)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
por: Sapkota, Bishu, et al.
Publicado: (2013)

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma
por: Ruiz-Garcia, Erika, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2lh69tif7befjm5b4tvl44lsga